Medicare and its beneficiaries wasted $111 million on generic drugs, according to a report by the Office of the Inspector General. The OIG investigation found that payment amounts were much higher than market prices for an extended period for newly available generic drugs under review. Generic versions of certain drugs were administered or dispensed to beneficiaries, but Medicare was still paying brand-level prices. Report